9th Annual Biomarkers Congress
28th Annual Miami Breast Cancer Conferenceâ„¢
Fontainebleau Miami Beach Hotel
4441 Collins Ave.
Miami, Florida
http://www.cancerlearning.com/index.cfm/fuseaction/conference.showOverview/id/5/conference_id/535
   Speakers
   --------

   Andy Minn,
   Ann Chambers,
   Dana Faratian,
   Daniel A. Osman,
   Daniel Hayes,
   Debu Tripathy,
   Emiel J. T. Rutgers,
   Fattaneh Abbas-Zadeh Tavassoli,
   Frank A. Vicini,
   Henry Kuerer,
   Hiram S. Cody III ,
   Hyman B. Muss,
   Isaiah J. Fidler,
   J. Michael Dixon,
   Judith Hurley,
   Laura Esserman,
   Lisa Carey,
   Lori J. Pierce,
   Mark E. Robson,
   Mark Pegram,
   Mattia Intra,
   Melvin Silverstein,
   Norman Wolmark,
   Patrick I. Borgen,
   R. Douglas Macmillan,
   MD, FRCPath
   Robert DerHagopian,
   Samuel Aparicio,
   Timothy Whelan,
   V. Suzanne Klimberg,
   William F. Symmans

   Overview and Purpose
   The optimal care of patients with breast cancer is rapidly changing as
   a result of advances in all aspects of patient care, including
   prevention, screening, and detection, as well as in the primary
   treatment modalities of surgery, radiation therapy, cytotoxic
   chemotherapy, and novel biologic therapies. There is an increasing
   focus on providing multidisciplinary care for patients with complex
   diseases such as breast cancer through the use of integrated teams of
   professionals representing the relevant treatment modalities,
   including surgery, radiation therapy, and systemic medical
   interventions. The multidisciplinary Miami Breast Cancer Conferenceâ„¢
   has been bringing together surgical, medical, and radiation
   oncologists for 28 years, with the aim of fostering awareness of the
   state-of-the-art treatments in each therapeutic area and encouraging
   cross-team cooperation in the clinic. At the 28th Annual Miami Breast
   Cancer Conference, pioneers of innovative approaches in each of these
   subspecialties will provide insight into the optimal multidisciplinary
   management of patients with breast cancer and its application to
   practice.

   Target Audience This educational program is directed toward medical,
   surgical, and radiation oncologists interested in the treatment of
   patients with breast cancer. Fellows, nurse practitioners, nurses,
   physician assistants, pharmacists, researchers, and other health care
   professionals interested in the treatment of breast cancer are also
   invited to attend. Learning Objectives At the conclusion of this
   congress, you should be able to:

     *  Assess data on the optimization of surgery for the treatment of
       early-stage breast cancer

     *  Examine recent advances in radiation therapy for the treatment of
       patients with breast cancer

     *  Discuss strategies for the prevention of familial breast cancer
       and management of hereditary risk, including prophylactic surgery
       and chemoprevention

     *  Appropriately integrate biomarkers, genomic assays, and other
       risk assessment tools into treatment decision making for
       early-stage breast cancer

     *  Review optimal strategies for endocrine therapy and management of
       bone health for patients with hormone receptor–positive breast
       cancer

     *  Identify appropriate strategies for the use of cytotoxic agents
       in the treatment of patients with early-stage and
       advanced/refractory breast cancer

     *  Discuss standard and novel therapeutic options for patients with
       HER2-overexpressing breast cancer, including patient selection
       strategies, combinatorial therapies, and options beyond
       progression on standard therapy

     *  Examine the efficacy of targeted agents and how to appropriately
       utilize them in the treatment of HER2– breast cancer

     *  Select eligible patients with breast cancer for promising
       clinical trials


   4441 Collins Ave., Miami, FL , 33140, United States

   Loading (May not complete on browsers without Javascript support)...

   Try again

Schedule of Presentations:

Wednesday, March 9, 2011
11:35:00 CME-Designated Satellite Symposium (Tentative)
11:40:00 Lunch on Own
12:50:00 Mini-Symposium
12:55:00 Welcome
13:00:00 Management of Benign Breast Problems J. Michael Dixon
13:05:00 Congenital Breast Anomalies J. Michael Dixon
13:15:00 Recurrent Infections and Fistulae Emiel J. T. Rutgers
13:30:00 Nipple Discharge and Gynecomastia Henry Kuerer
13:45:00 Benign Conditions (Pain, Cysts, Fibroadenomas, Bursitis): A US Perspective V. Suzanne Klimberg
14:00:00 Benign Conditions | A European Perspective R. Douglas Macmillan
14:15:00 San Antonio | Practice Changing Update Debu Tripathy
14:30:00 Question-and-Answer Session
15:00:00 Break in Exhibit Hall
15:25:00 Uncommon Malignancies | Case-Based Studies and Best Evidence Patrick I. Borgen
15:30:00 Occult Carcinoma Hiram S. Cody
15:45:00 Metaplastic Breast Cancers Fattaneh Abbas-Zadeh Tavassoli
16:00:00 Breast Sarcomas and Malignant Lymphoma Mattia Intra
16:15:00 Hereditary Breast Cancers Mark Robson
16:30:00 Medical and Legal Considerations Patrick I. Borgen
16:45:00 Question-and-Answer Session
17:30:00 Adjourn
18:00:00 Exhibit Hall Opens | Poster Session (non-CME) and Reception
Thursday, March 10, 2011
06:45:00 CME-Designated Satellite Symposium (Tentative)
06:50:00 Breakfast in Exhibit Hall
07:55:00 Opening Remarks Daniel A. Osman
08:00:00 Transition From DIN to Invasive Carcinoma
08:05:00 New Classification of DCIS: Ductal Intraepithelial Neoplasia (DIN) Fattaneh Abbas-Zadeh Tavassoli
08:15:00 Long-Term Follow-up of Surgery for DIN | Predicting Risk of Local Recurrence Mattia Intra
08:30:00 Is There a Role for Preoperative Therapy in DCIS? Henry Kuerer
08:45:00 Management of DCIS Using the 2011 USC | Van Nuys Prognostic Index Melvin Silverstein
09:00:00 Addressing the Overdiagnosis Dilemma in DCIS: Prescription for Change Laura Esserman
09:15:00 Histologic and Biologic Markers to Differentiate Indolent From Aggressive DCIS Henry Kuerer
09:30:00 Transition From Intraepithelial to Invasive Breast Cancer Fattaneh Abbas-Zadeh Tavassoli
09:45:00 Break in Exhibit Hall
10:30:00 Breast Conservation Surgery for BRCA1/2 Carriers Lori J Pierce
10:45:00 Predisposition Syndromes Associated With Breast Cancer Mark Robson
10:55:00 Controversies in Preoperative MRI in Breast Cancer
11:00:00 American View (Pros and Cons) Daniel Hayes
11:15:00 One European View Emiel J. T. Rutgers
11:20:00 Radiation Therapy | Indications New Techniques Comparison With Standard Radiation Therapy
11:30:00 Accelerated Partial-Breast Irradiation in Both DCIS and Invasive Carcinoma Frank A Vicini
11:45:00 Hypofractionation | How Frequent? Dose Fractions? Impact of Boost? Timothy Whelan
12:00:00 Intensity-Modulated Radiation Therapy | Standardization of Technique and Acute and Late Toxicities Lori J. Pierce
12:15:00 Intraoperative Radiation Therapy | American Technique Melvin Silverstein
12:30:00 Intraoperative Radiation Therapy | European Technique Mattia Intra
12:45:00 Lunch | Satellite Symposium (Tentative) or Hands-On Workshop (Space Limited, Preregistration Required)
12:50:00 Lunch on Own
13:55:00 Session B Debu Tripathy
13:55:00 Sessions 3 | Practical Tips on "How I Do It"
14:00:00 Practical Tips for Planning Breast Surgery R. Douglas Macmillan
14:15:00 How to Do a Nipple-Sparing Mastectomy With Breast Reconstruction Patrick I. Borgen
14:15:00 Session B | Tailoring Adjuvant and Neoadjuvant Hormonal Therapy Lisa A. Carey
14:30:00 Session B | Can We Personalize Adjuvant Chemotherapy? William F. Symmans
14:30:00 How to Do a Wide Local Excision (How Wide? Which Margins Matter?) J. Michael Dixon
14:45:00 Axillary Reverse Mapping | Clinical Significance of Differentiating Arm and Breast Lymphatics V. Suzanne Klimberg
14:45:00 Session B | Is There a Role for Fluoropyrimidines in Adjuvant Therapy? Hyman B. Muss
15:00:00 Session B | Adjuvant/Neoadjuvant Platinum-Based Chemotherapy Judith Hurley
15:00:00 How to Do a Sentinel Node Biopsy: Axillary Dissections and Internal Mammary Biopsy Hiram S. Cody
15:15:00 Role of Axillary Dissection After a Positive Sentinel Node Norman Wolmark
15:15:00 Session B | The Latest in Bone-Targeted Therapy and Outcomes Debu Tripathy
15:30:00 Prognosis and Lymph Nodes | Is It Time to Exit Lymph Node Status? Emiel J. T. Rutgers
15:30:00 Session B | Emerging Role of Nanotechnology in Breast Cancer Diagnosis and Treatment Richard J. Cote
15:45:00 Session B | State-of-the-Art Biologic Adjuvant Therapy Daniel Hayes
15:45:00 Margin Radiofrequency Ablation | Potential as an Adjuvant to Invasive Surgery V. Suzanne Klimberg
16:00:00 Break in Exhibit Hall
16:00:00 Sessions 3 | Break in Exhibit Hall
16:30:00 Role of PET/CT in Patients With Locoregional Recurrence Emiel J. T. Rutgers
16:30:00 Sessions 3 | Panel Discussion
16:45:00 Management of Locoregional Recurrence | Palliation Versus Intent to Cure Frank A Vicini
17:00:00 Panel Discussion
17:30:00 Adjourn
17:30:00 Sessions 3 | Adjourn
17:35:00 Sessions 3 | "Meet the Professor" Sessions Timothy Whelan, Melvin Silverstein, Mark Robson, Mattia Intra, Laura Esserman, Patrick I. Borgen
19:00:00 Sessions 3 | "Get Acquainted" Reception in Exhibit Hall
Friday, March 11, 2011
06:45:00 CME-Designated Satellite Symposium (Tentative)
06:50:00 Breakfast in Exhibit Hall
08:00:00 Breast Cancer Brain Metastasis | "The Seed and the Soil" Isaiah J. Fidler
08:30:00 Is Primary Tumor a "Blueprint" for Metastases? How Breast Cancer Begins and Spreads Samuel Aparicio
08:45:00 Can Gene Signatures in Primary Tumor Predict the Site of Metastasis and Resistance to Treatment | Implications for Prevention Andy Minn
09:00:00 Breast Cancer Stem Cells | "Treating the Core" Daniel Hayes
09:15:00 Biologic Information Obtained From Circulating and Disseminated Tumor Cells Richard J. Cote
09:30:00 Dormancy of Disseminated Tumor Cells: What Triggers Activation? Ann Chambers
09:45:00 Break in Exhibit Hall
10:30:00 Accelerating Drug Development and Biomarker Discovery (ISPY) Laura Esserman
10:35:00 Current Management and Future Perspectives of Different Molecular Subtypes
10:40:00 Debate | Should genomic profiles be used routinely to determine who should receive adjuvant therapy?
10:45:00 Pro Norman Wolmark
10:55:00 Con J. Michael Dixon
11:05:00 Arbiter Daniel Hayes
11:15:00 Luminal A and B | Differences Regarding Diagnosis, Prognosis, and Treatment Daniel Hayes
11:30:00 Triple-Negative and Basal Cancers | Beyond PARP Inhibitors Lisa A Carey
11:45:00 HER2-Positive Breast Cancer | Subtypes With Different Clinical Outcomes Mark Pegram
12:00:00 Predicting Survival From Adjuvant Therapy William F. Symmans
12:15:00 Therapy Targeting Cell Signaling Pathways Dana Faratian
12:30:00 Lunch | Satellite Symposium (Tentative) or Hands-On Workshop (Space Limited, Preregistration Required)
12:35:00 Lunch on Own
13:55:00 Session B Debu Tripathy
13:55:00 Session A Patrick I. Borgen
14:00:00 Sessions A | Controversy Regarding Postmastectomy Radiation Therapy in Patients With 1-3 Positive Axillary Nodes Lori J Pierce
14:00:00 Session B | Understanding How Cancer Cells Acquire Metastatic and Treatment-Resistant Phenotypes Andy Minn
14:15:00 Session B | Recognition of Breast Cancer Heterogeneity in Targeted Treatment Samuel Aparicio
14:15:00 Session A | Prophylactic Contralateral Mastectomy: Current Recommendations, Technique, and Outcome Hiram S. Cody
14:30:00 Session B | Current Thinking on Antiangiogenic Therapy Lisa A Carey
14:30:00 Session A | Round Block Excision: Oncoplastic Surgery for Non–Plastic Surgeons Melvin Silverstein
14:45:00 Session A | Does Local Surgery Have a Role in Metastatic Disease? Mattia Intra
14:45:00 Session B | What's Next in HER2-Targeted Therapy? Mark Pegram
15:00:00 Session A | Oncoplastic Techniques in Breast-Conserving Surgery: Volume Displacement R. Douglas Macmillan
15:00:00 Session B | Does Tumor Dormancy Offer a Therapeutic Target? Ann Chambers
15:15:00 Session B | Managing Breast Cancer in the Elderly: Avoiding Under/Overtreatment Hyman B. Muss
15:15:00 Session A | Surveillance Imaging of the Reconstructed Breast Laura Esserman
15:30:00 Session A | Oncoplastic Techniques in Breast-Conserving Surgery: Volume Replacement R. Douglas Macmillan
15:30:00 Session B | Individualizing First-line Therapy for Metastatic Breast Cancer Judith Hurley
15:45:00 Session A | Break in Exhibit Hall
15:45:00 Session B | Emerging Cytotoxic Agents for Relapsed/Refractory Metastatic Breast Cancer Mark Pegram
16:00:00 Session B | Break in Exhibit Hall
16:15:00 Session A | Panel Discussion: Question-and-Answer Session
16:30:00 Session B | Panel Discussion: Question-and-Answer Session
17:00:00 Session A | Adjourn
17:00:00 Session B | Adjourn
17:10:00 Session B | "Meet the Professor" Sessions William F. Symmans, Mark Pegram, Andy Minn, Richard J Cote, Lisa A. Carey, Samuel Aparicio, Hyman B. Muss
18:30:00 Session B | Gala Reception on the Ocean Lawn
Saturday, March 12, 2011
06:45:00 CME-Designated Satellite Symposium (Tentative)
06:50:00 Breakfast in Exhibit Hall
08:00:00 Prediction | Breast Cancer Management in 5-10 Years Norman Wolmark
08:15:00 Systems Biology Approach to Understanding Breast Cancer Biology Dana Faratian
08:30:00 When Should Clinical Trial Results Change Practice? Laura Esserman
08:45:00 Postoperative Management of Patients Who Receive Preoperative Therapy Hyman B. Muss
09:00:00 Biomarkers for Resistance in Residual Tumor William F. Symmans
09:15:00 Indications for Postmastectomy Radiation in Patients Treated With Preoperative Chemotherapy Timothy Whelan
09:30:00 State-of-the-Art Surveillance After Early Breast Cancer Debu Tripathy
09:45:00 Break in Exhibit Hall
10:30:00 Roundtable Discussion With Audience Participation on Current Issues in Breast Cancer | Follow-up, Treatment Side Effects, Costs, End-of-Life Care, and "Burn-Out" Norman Wolmark, Timothy Whelan, Debu Tripathy, William F. Symmans, Hyman B. Muss, Dana Faratian, Laura Esserman, J. Michael Dixon, Patrick I. Borgen
11:45:00 Closing Remarks Daniel A. Osman
12:00:00 Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.